Psoriasis
Conditions
Interventions
Sponsors
Huazhong University Of Science And Technology Union Shenzhen Hosipital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adults (age = 18 years old) with moderate to severe plaque psoriasis diagnosed by clinical physician with Guideline for the diagnosis and treatment of psoriasis in China. 2. Patients who started treatment with guselkumab after April 2024 (retrospective enrollment before the official launch of the program, prospective enrollment after the official launch of the program) 3. For the patients who initiated but discontinued guselkumab before the time of study initiation (estimated in Sep. 2024), an informed consent form (ICF) can be waived if exemption from the institutional review board (IRB) can be obtained. Other patients must sign a participation agreement/ICF allowing source data verification in accordance with local requirements.
Exclusion criteria
Exclusion criteria: 1. Require a combination of other systemic treatment for psoriasis at the initiation of guselkumab. 2. Participation in any dermatology or rheumatology trial, concurrent or within the last 30 days of initiating date. 3. Patients who are participating in other interventional studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity Index (PASI) ; | — |
Secondary
| Measure | Time frame |
|---|---|
| static Physician Global Assessment (sPGA);Body surface area (BSA);Dermatology Life Quality Index (DLQI) ;Scalp-Specific Investigator's Global Assessment (ss-IGA);Nail Psoriasis Area and Severity Index (NAPSI) ;PGA of the hands and/or feet (hfPGA);static Physician’s Global Assessment of Genitalia ; | — |
Countries
China
Contacts
Public ContactLiu Xiaoming
Huazhong University Of Science And Technology Union Shenzhen Hosipital
Outcome results
None listed